---
pmid: '29656858'
title: A Recurrent De Novo PACS2 Heterozygous Missense Variant Causes Neonatal-Onset
  Developmental Epileptic Encephalopathy, Facial Dysmorphism, and Cerebellar Dysgenesis.
authors:
- Olson HE
- Jean-Marçais N
- Yang E
- Heron D
- Tatton-Brown K
- van der Zwaag PA
- Bijlsma EK
- Krock BL
- Backer E
- Kamsteeg EJ
- Sinnema M
- Reijnders MRF
- Bearden D
- Begtrup A
- Telegrafi A
- Lunsing RJ
- Burglen L
- Lesca G
- Cho MT
- Smith LA
- Sheidley BR
- Moufawad El Achkar C
- Pearl PL
- Poduri A
- Skraban CM
- Tarpinian J
- Nesbitt AI
- Fransen van de Putte DE
- Ruivenkamp CAL
- Rump P
- Chatron N
- Sabatier I
- De Bellescize J
- Guibaud L
- Sweetser DA
- Waxler JL
- Wierenga KJ
- DDD Study
- Donadieu J
- Narayanan V
- Ramsey KM
- C4RCD Research Group
- Nava C
- Rivière JB
- Vitobello A
- Tran Mau-Them F
- Philippe C
- Bruel AL
- Duffourd Y
- Thomas L
- Lelieveld SH
- Schuurs-Hoeijmakers J
- Brunner HG
- Keren B
- Thevenon J
- Faivre L
- Thomas G
- Thauvin-Robinet C
journal: Am J Hum Genet
year: '2018'
full_text_available: false
pmcid: PMC5986694
doi: 10.1016/j.ajhg.2018.03.005
---

# A Recurrent De Novo PACS2 Heterozygous Missense Variant Causes Neonatal-Onset Developmental Epileptic Encephalopathy, Facial Dysmorphism, and Cerebellar Dysgenesis.
**Authors:** Olson HE, Jean-Marçais N, Yang E, Heron D, Tatton-Brown K, van der Zwaag PA, Bijlsma EK, Krock BL, Backer E, Kamsteeg EJ, Sinnema M, Reijnders MRF, Bearden D, Begtrup A, Telegrafi A, Lunsing RJ, Burglen L, Lesca G, Cho MT, Smith LA, Sheidley BR, Moufawad El Achkar C, Pearl PL, Poduri A, Skraban CM, Tarpinian J, Nesbitt AI, Fransen van de Putte DE, Ruivenkamp CAL, Rump P, Chatron N, Sabatier I, De Bellescize J, Guibaud L, Sweetser DA, Waxler JL, Wierenga KJ, DDD Study, Donadieu J, Narayanan V, Ramsey KM, C4RCD Research Group, Nava C, Rivière JB, Vitobello A, Tran Mau-Them F, Philippe C, Bruel AL, Duffourd Y, Thomas L, Lelieveld SH, Schuurs-Hoeijmakers J, Brunner HG, Keren B, Thevenon J, Faivre L, Thomas G, Thauvin-Robinet C
**Journal:** Am J Hum Genet (2018)
**DOI:** [10.1016/j.ajhg.2018.03.005](https://doi.org/10.1016/j.ajhg.2018.03.005)
**PMC:** [PMC5986694](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986694/)

## Abstract

1. Am J Hum Genet. 2018 May 3;102(5):995-1007. doi: 10.1016/j.ajhg.2018.03.005. 
Epub 2018 Apr 12.

A Recurrent De Novo PACS2 Heterozygous Missense Variant Causes Neonatal-Onset 
Developmental Epileptic Encephalopathy, Facial Dysmorphism, and Cerebellar 
Dysgenesis.

Olson HE(1), Jean-Marçais N(2), Yang E(3), Heron D(4), Tatton-Brown K(5), van 
der Zwaag PA(6), Bijlsma EK(7), Krock BL(8), Backer E(9), Kamsteeg EJ(10), 
Sinnema M(11), Reijnders MRF(10), Bearden D(12), Begtrup A(13), Telegrafi A(13), 
Lunsing RJ(14), Burglen L(15), Lesca G(16), Cho MT(13), Smith LA(1), Sheidley 
BR(1), Moufawad El Achkar C(1), Pearl PL(1), Poduri A(1), Skraban CM(17), 
Tarpinian J(17), Nesbitt AI(8), Fransen van de Putte DE(7), Ruivenkamp CAL(7), 
Rump P(6), Chatron N(16), Sabatier I(18), De Bellescize J(19), Guibaud L(20), 
Sweetser DA(21), Waxler JL(21), Wierenga KJ(22); DDD Study; Donadieu J(23), 
Narayanan V(24), Ramsey KM(24); C4RCD Research Group; Nava C(25), Rivière 
JB(26), Vitobello A(26), Tran Mau-Them F(26), Philippe C(26), Bruel AL(26), 
Duffourd Y(26), Thomas L(27), Lelieveld SH(28), Schuurs-Hoeijmakers J(29), 
Brunner HG(30), Keren B(25), Thevenon J(31), Faivre L(31), Thomas G(27), 
Thauvin-Robinet C(32).

Author information:
(1)Epilepsy Genetics Program, Department of Neurology, Division of Epilepsy and 
Clinical Neurophysiology, Boston Children's Hospital, Boston, MA 02115, USA.
(2)Centre de Génétique Médicale, Centre de Référence "Déficiences 
Intellectuelles de causes rares," CHU de Dijon Bourgogne, 21079 Dijon, France; 
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du 
Développement (TRANSLAD), CHU de Dijon Bourgogne, 21079 Dijon, France.
(3)Department of Radiology, Boston Children's Hospital, Boston, MA 02115, USA.
(4)AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, 75013, 
Paris, France; Centre de Référence "déficiences intellectuelles de causes 
rares," 75013 Paris, France; Groupe de Recherche Clinique (GRC) "déficience 
intellectuelle et autisme" UPMC, 75013 Paris, France.
(5)St George's University of London, London, UK and South West Thames Regional 
Genetics Service, St George's Universities NHS Foundation Trust, London SW17 
0RE, UK.
(6)University of Groningen, University Medical Center Groningen, Department of 
Genetics, 9700 RB Groningen, the Netherlands.
(7)Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA 
Leiden, the Netherlands.
(8)Department of Pathology and Laboratory Medicine, Division of Genomic 
Diagnostics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, 
USA; Department of Pathology and Laboratory Medicine, Perelman School of 
Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
(9)Genomic Diagnostics Laboratory, Manchester Centre for Genomic Medicine, 
Central Manchester University Hospitals, NHS Foundation Trust, Saint Mary's 
Hospital, Manchester M13 9WL, UK.
(10)Department of Human Genetics, Radboud University Medical Center, Nijmegen 
6500 HB, the Netherlands; Donders Institute for Brain, Cognition, and Behavior, 
Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.
(11)Department of Clinical Genetics and School for Oncology & Developmental 
Biology (GROW), Maastricht University Medical Center, Maastricht 6229 ER, the 
Netherlands.
(12)Department of Neurology, Division of Child Neurology, University of 
Rochester School of Medicine, Rochester, NY 14642, USA.
(13)GeneDx program, Gaithersburg, MD 20877, USA.
(14)University of Groningen, University Medical Center Groningen, Department of 
Child Neurology, 9713 GZ Groningen, the Netherlands.
(15)Centre de Référence Maladies Rares "Malformations et maladies congénitales 
du cervelet," Département de Génétique Médicale, APHP, GHUEP, Hôpital Trousseau, 
75012 Paris, France; GRC ConCer-LD, Sorbonne Universités, UPMC Univ 06, 75019 
Paris, France; INSERM U1141, Université Paris Diderot, 75019 Paris, France.
(16)Department of Medical Genetics, Lyon University Hospital, 69677 Lyon, 
France; CNRS UMR 5292, INSERM U1028, CNRL, 69500 Lyon, France; Université Claude 
Bernard Lyon 1, GHE, 69100 Lyon, France.
(17)Division of Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 
19104, USA; Department of Pediatrics, Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, PA 19104, USA.
(18)Department of Pediatric Neurology, Lyon University Hospital, 69677 Lyon, 
France.
(19)Department of clinical epileptology, sleep and functional neurology in 
children, Lyon University Hospital, 69677 Lyon, France.
(20)Université Claude Bernard Lyon I, CHU de Lyon, 69677 Lyon, France; Service 
de radiologie, Hôpital-Femme-Mère-Enfant, Hospices Civils de Lyon, 69677 Lyon, 
France.
(21)Division of Medical Genetics, Department of Pediatrics and Metabolism, 
MassGeneral Hospital for Children, Boston, MA 02114, USA.
(22)Department of Pediatrics, Oklahoma University Health Sciences Center 
(OUHSC), Oklahoma City, OK 73104, USA.
(23)Service d'hémato-oncologie pédiatrique, Hôpital Trousseau, APHP, 75012 
Paris, France.
(24)Center for Rare Childhood Disorders, Translational Genomics Research 
Institute (TGen), Phoenix, AZ 85004, USA.
(25)AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, 75013 
Paris, France; UPMC, Inserm, CNRS, UM 75, U 1127, UMR 7225, ICM, Paris 75013, 
France.
(26)Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du 
Développement (TRANSLAD), CHU de Dijon Bourgogne, 21079 Dijon, France; Inserm 
UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, 
21079 Dijon, France.
(27)Department of Microbiology and Molecular Genetics and University of 
Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, 
Pittsburgh, PA 15219, USA.
(28)Department of Human Genetics, Radboud University Medical Center, Nijmegen 
6500 HB, the Netherlands; Radboud Institute for Molecular Life Sciences, Radboud 
University Medical Center, Nijmegen 6500 HB, the Netherlands.
(29)Department of Human Genetics, Radboud University Medical Center, Nijmegen 
6500 HB, the Netherlands.
(30)Department of Human Genetics, Radboud University Medical Center, Nijmegen 
6500 HB, the Netherlands; Donders Institute for Brain, Cognition, and Behavior, 
Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands; Department 
of Clinical Genetics and School for Oncology & Developmental Biology (GROW), 
Maastricht University Medical Center, Maastricht 6229 ER, the Netherlands.
(31)Centre de Génétique Médicale, Centre de Référence "Déficiences 
Intellectuelles de causes rares," CHU de Dijon Bourgogne, 21079 Dijon, France; 
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du 
Développement (TRANSLAD), CHU de Dijon Bourgogne, 21079 Dijon, France; Inserm 
UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, 
21079 Dijon, France.
(32)Centre de Génétique Médicale, Centre de Référence "Déficiences 
Intellectuelles de causes rares," CHU de Dijon Bourgogne, 21079 Dijon, France; 
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du 
Développement (TRANSLAD), CHU de Dijon Bourgogne, 21079 Dijon, France; Inserm 
UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, 
21079 Dijon, France. Electronic address: christel.thauvin@chu-dijon.fr.

Erratum in
    Am J Hum Genet. 2018 Oct 4;103(4):631. doi: 10.1016/j.ajhg.2018.09.002.

Developmental and epileptic encephalopathies (DEEs) represent a large clinical 
and genetic heterogeneous group of neurodevelopmental diseases. The 
identification of pathogenic genetic variants in DEEs remains crucial for 
deciphering this complex group and for accurately caring for affected 
individuals (clinical diagnosis, genetic counseling, impacting medical, 
precision therapy, clinical trials, etc.). Whole-exome sequencing and intensive 
data sharing identified a recurrent de novo PACS2 heterozygous missense variant 
in 14 unrelated individuals. Their phenotype was characterized by epilepsy, 
global developmental delay with or without autism, common cerebellar dysgenesis, 
and facial dysmorphism. Mixed focal and generalized epilepsy occurred in the 
neonatal period, controlled with difficulty in the first year, but many improved 
in early childhood. PACS2 is an important PACS1 paralog and encodes a 
multifunctional sorting protein involved in nuclear gene expression and pathway 
traffic regulation. Both proteins harbor cargo(furin)-binding regions (FBRs) 
that bind cargo proteins, sorting adaptors, and cellular kinase. Compared to the 
defined PACS1 recurrent variant series, individuals with PACS2 variant have more 
consistently neonatal/early-infantile-onset epilepsy that can be challenging to 
control. Cerebellar abnormalities may be similar but PACS2 individuals exhibit a 
pattern of clear dysgenesis ranging from mild to severe. Functional studies 
demonstrated that the PACS2 recurrent variant reduces the ability of the 
predicted autoregulatory domain to modulate the interaction between the PACS2 
FBR and client proteins, which may disturb cellular function. These findings 
support the causality of this recurrent de novo PACS2 heterozygous missense in 
DEEs with facial dysmorphim and cerebellar dysgenesis.

Copyright © 2018 American Society of Human Genetics. All rights reserved.

DOI: 10.1016/j.ajhg.2018.03.005
PMCID: PMC5986694
PMID: 29656858 [Indexed for MEDLINE]
